Treatment of Infertility in Women With Polycystic Ovary Syndrome

Last updated: September 28, 2007
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Overall Status: Completed

Phase

3

Condition

Pregnancy

Reproductive Health

Polycystic Ovarian Syndrome

Treatment

N/A

Clinical Study ID

NCT00068861
NICHD-PPCOS
  • Ages 18-39
  • Female

Study Summary

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting up to 10% of women. The primary symptoms of PCOS are menstrual irregularities, increased body and facial hair, acne, and infertility. This study will test a combination of medications in women with PCOS to determine which works best to overcome infertility.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Eight or fewer menstrual cycles in the past year or intermenstrual periods of 45 days or longer

  • Elevated testosterone level

  • Good general health

  • Sperm concentration in partner of 20 million/ml or greater

  • Ability to have intercourse 2-3 times per week

  • One functional fallopian tube and normal uterine cavity

Study Design

Total Participants: 678
Study Start date:
November 01, 2002
Estimated Completion Date:
February 28, 2006

Study Description

PCOS is characterized by excess circulating androgen levels and chronic anovulation. The fundamental pathophysiologic defect is unknown, but PCOS is characterized by insulin resistance and compensatory hyperinsulinemia. Improvements in insulin sensitivity in PCOS women, either through lifestyle changes or through pharmaceutical intervention, have consistently resulted in a marked improvement in the reproductive and metabolic abnormalities in PCOS. Resumption of ovulation occurs in up to 70% of women treated for PCOS. This study will evaluate the safety and effectiveness of clomiphene citrate and metformin XR in achieving a successful pregnancy in infertile PCOS women.

Women with PCOS who are seeking pregnancy will be enrolled in this study. Women will be randomized to one of three different treatment arms: A) metformin XR 1000 mg twice/day; B) clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle); or C) metformin XR 1000 mg twice/day with clomiphene citrate 50 mg/day for 5 days (day 3-7 of cycle). Women will continue on study medications for 30 weeks, 6 treatment cycles, or until they become pregnant. Progesterone levels will be drawn weekly to monitor ovulation.

Connect with a study center

  • University of Alabama at Birmingham

    Birmingham, Alabama 35249
    United States

    Site Not Available

  • University of California at San Diego

    La Jolla, California 92037
    United States

    Site Not Available

  • Stanford University

    Stanford, California 94305
    United States

    Site Not Available

  • University of Colorado

    Aurora, Colorado 80045
    United States

    Site Not Available

  • Wayne State

    Detroit, Michigan 48201
    United States

    Site Not Available

  • University of Medicine and Dentistry New Jersey

    Newark, New Jersey 07103
    United States

    Site Not Available

  • Penn State

    Hershey, Pennsylvania 17033
    United States

    Site Not Available

  • University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • University of Texas Southwestern Medical Center

    Dallas, Texas 75390
    United States

    Site Not Available

  • Baylor College of Medicine

    Houston, Texas 77030
    United States

    Site Not Available

  • Virginia Commonwealth University

    Richmond, Virginia 23298
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.